BioDiscovery start new analysis software program for cancer research Affymetrix and BioDiscovery.
Soheil Shams, BioDiscovery's Chief Scientific Officer. ‘The high quality data from the Affymetrix assays performs very well in our software for detecting copy number variants. We’ve customers all over the world which have been leveraging the CytoScan Cytogenetics Suite and OncoScan platforms for copy number evaluation from different types of cancers samples, and we're very happy to be able to give this joint solution to greatly help scientists to gain further insights into cancers biology.’.. Affymetrix, BioDiscovery start new analysis software program for cancer research Affymetrix and BioDiscovery, Inc. ‘CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit are key parts of our cancer portfolio,’ says Dr. Andy Last, Executive Vice President and Chief Operating Officer at Affymetrix.Median general survival in masitinib compares favorably to that of imatinib in individuals with KIT exon 11 mutation especially subpopulation. Adverse events occurred through the first year mainly, with good long term tolerance experienced thereafter. With a median follow-up of 72 a few months, the updated overall survival data for the Package exon 11 mutation subpopulation> III. Considering the promising very long term efficacy seen in survival and safety from phase II, there exists a compelling motive to perform a head-to-head comparison of masitinib against imatinib in first-line setting. On May 11th 2012, an Independent Data Monitoring Committee offered its positive opinion to continue this scholarly study. This potential, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III research compares efficacy and security of masitinib to the active control of imatinib in first-collection treatment of patients with advanced GIST.